Royalty Pharma plc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2025: USD 290.13 M

Royalty Pharma plc Selling, General, and Administrative Expenses (SG&A) is USD 290.13 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 30.97% change year over year. Selling, general, and administrative (SG&A) expenses are the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company.
  • Royalty Pharma plc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 221.52 M, a -15.28% change year over year.
  • Royalty Pharma plc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 261.46 M, a 36.74% change year over year.
  • Royalty Pharma plc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 191.21 M, a 2.28% change year over year.
  • Royalty Pharma plc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 186.96 M, a 59.68% change year over year.
Key Data
Date Selling, General, and Administrative Expenses (SG&A) Research and Development (R&D) Expenses Revenue Revenue